Momentum has been gathering behind efforts to reclassify marijuana under the Controlled Substances Act (CSA). Regardless of how marijuana is rescheduled under federal law, the Food and Drug Administration (FDA) could consider medical marijuana products to be unapproved “new drugs” subject to regulation under the Food, Drug, and Cosmetic Act (FDCA).

Read the article on Law.com here.